Biohackers Gear Up for Genome Editing
By Heidi Ledford,
Nature News
| 08. 26. 2015
Untitled Document
A complete lack of formal scientific training has not kept Johan Sosa from dabbling with one of the most powerful molecular-biology tools to come along in decades.
Sosa has already used CRISPR, a three-year-old technology that makes targeted modifications to DNA, in test-tube experiments. Next week, he hopes to try the method in yeast and, later, in the model plant Arabidopsis thaliana.
Hailed for its simplicity and versatility, CRISPR allows scientists to make specific changes to a gene’s sequence more easily than ever before. Researchers have used CRISPR to edit genes in everything from bacteria to human embryos; the technique holds the potential to erase genetic defects from family pedigrees plagued by inherited disease, treat cancer in unprecedented ways or grow human organs in pigs. One researcher has even proposed modifying the elephant genome to produce a cold-adapted replica of the long-extinct woolly mammoth.
Such feats are beyond the reach of do-it-yourself (DIY) ‘biohackers’, a growing community of amateur biologists who often work in community laboratories, which typically charge a recurring fee for...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...